New cancer drug EXS74539 enters first human trials
NCT ID NCT07517198
First seen Apr 29, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also watch for any signs that the drug is shrinking tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
START Dallas
RECRUITINGFort Worth, Texas, 76104, United States
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
-
Start Lacn
RECRUITINGLos Angeles, California, 90025, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EXS74539 (REC-4539), an oral drug
What this could lead to
If successful, this could lead to a new treatment option for several types of solid tumors.
What could go wrong
This is an early Phase 1 trial with only 40 participants, focused on safety and dosing. It is too early to know if the drug will be effective or have manageable side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.